Astellas Pharma and Pfizer announced that they received an approval by the FDA of a supplemental New Drug Application for XTANDI®.
Astellas Pharma and Pfizer today announced that the companies received an approval by the FDA of a supplemental New Drug Application for XTANDI® (enzalutamide), following FDA expedited development and review programs (Priority Review designation, Fast Track designation, Real-time Oncology Review),…